Sickle cell disease is caused by a point mutation, the simplest type of genetic change possible. A single letter in the DNA code of the gene responsible for making hemoglobin (the protein that carries oxygen in red blood cells) is swapped for a different one. That one-letter change alters the shape and behavior of hemoglobin in ways that cascade through the entire body.
The Single Nucleotide Change
The mutation sits in the beta-globin gene, specifically at codon 6, which is essentially the sixth “word” in the gene’s instruction sequence. In that codon, an adenine (A) is replaced by a thymine (T). This is classified as a point mutation because it involves just one nucleotide, the smallest unit of DNA. Despite being so small, this swap changes the amino acid the gene codes for: instead of glutamic acid, the protein is built with valine at that position.
That amino acid swap matters because glutamic acid and valine have very different chemical personalities. Glutamic acid is hydrophilic, meaning it interacts well with the watery environment inside a red blood cell. Valine is hydrophobic, meaning it repels water and tends to stick to other hydrophobic surfaces. This gives the altered hemoglobin, called hemoglobin S (HbS), a sticky patch on its surface that normal hemoglobin doesn’t have.
How One Amino Acid Changes Red Blood Cells
Under normal conditions, hemoglobin molecules float independently inside red blood cells, picking up oxygen in the lungs and releasing it throughout the body. Hemoglobin S behaves the same way when it’s carrying oxygen. The problem starts when it releases oxygen. In its deoxygenated state, the sticky hydrophobic patch on one HbS molecule locks onto a complementary spot on a neighboring HbS molecule, and those molecules begin stacking into long, rigid chains called polymers.
These polymers act like internal scaffolding, forcing the normally round, flexible red blood cell into a stiff crescent or “sickle” shape. The process accelerates as cell water content drops: dehydrated red blood cells have a higher concentration of HbS, which makes polymerization happen faster and under less severe oxygen conditions. In dense, dehydrated cells, HbS polymers can even form under normal oxygen pressure, not just in low-oxygen environments.
Sickled cells are fragile and break apart much sooner than healthy ones. A normal red blood cell lives about 120 days. In sickle cell disease, the average lifespan drops to roughly 64 days, with some cells lasting as few as 35 days. This rapid destruction is what causes the chronic anemia that gives the disease part of its name.
How Sickle Cell Is Inherited
Sickle cell disease follows an autosomal recessive pattern, meaning a person needs to inherit a copy of the mutated gene from both parents to develop the disease. Inheriting one mutated copy and one normal copy results in sickle cell trait, not sickle cell disease. People with sickle cell trait typically produce about 60% normal hemoglobin and 40% hemoglobin S, enough normal hemoglobin to prevent significant sickling under ordinary conditions.
The most common and generally most severe form is homozygous HbSS, where both copies of the beta-globin gene carry the sickle mutation. But sickle cell disease also occurs when the sickle gene is paired with certain other beta-globin mutations. Inheriting one sickle gene alongside one gene for hemoglobin C produces HbSC disease, which is particularly common in West Africa. Inheriting one sickle gene with a beta-thalassemia gene produces sickle beta-thalassemia, which ranges from mild to severe depending on the specific thalassemia mutation involved. When the thalassemia gene produces zero normal hemoglobin (beta-zero thalassemia), the disease is often as severe as HbSS.
Why the Mutation Persists: Malaria Protection
A mutation this harmful would normally become rare over generations, since it shortens life. Sickle cell persists at high frequencies in parts of Africa, the Mediterranean, and South Asia because carrying just one copy of the gene offers strong protection against malaria. Children with sickle cell trait are 50% to 90% less likely to develop severe malaria or die from it compared to children with two normal hemoglobin genes.
The protection works through several overlapping mechanisms. When the malaria parasite infects a red blood cell carrying HbS, the parasite’s own oxygen consumption lowers the oxygen level inside that cell, triggering HbS polymerization. This stunts the parasite’s growth and development. The sickling also changes the surface of the infected red blood cell in ways that make it easier for the immune system’s macrophages to recognize and destroy it. Additionally, the altered cell surface disrupts a key parasite adhesion protein, reducing the ability of infected cells to stick to blood vessel walls, which is one of the main ways severe malaria causes organ damage. Even specific small RNA molecules found at higher levels in sickle trait red blood cells can integrate into parasite genetic material and interfere with its ability to grow.
This is a classic example of what geneticists call heterozygote advantage: two copies of the gene cause serious disease, zero copies leave you vulnerable to malaria, but one copy hits a survival sweet spot.
Gene Therapies Targeting the Mutation
In December 2023, the FDA approved two gene therapies for sickle cell disease in patients 12 and older, both representing fundamentally new approaches. One, called Casgevy, is the first approved therapy using CRISPR gene-editing technology. Rather than fixing the sickle mutation directly, it edits a different part of the patient’s DNA to reactivate production of fetal hemoglobin, a form of hemoglobin that humans naturally produce before birth but mostly stop making in infancy. Fetal hemoglobin doesn’t polymerize the way HbS does, so raising its levels prevents red blood cells from sickling.
The second therapy, Lyfgenia, uses a viral delivery system to insert a modified gene into the patient’s blood stem cells. This gene produces a hemoglobin that functions like normal adult hemoglobin, reducing the proportion of HbS in each red blood cell and lowering the risk of sickling. Both therapies require collecting the patient’s own stem cells, modifying them in a lab, and transplanting them back after chemotherapy to clear the existing bone marrow. It’s an intensive process, but it targets the root genetic cause rather than managing symptoms.
The fact that both therapies work by changing what hemoglobin the body produces, rather than by correcting the original point mutation, reflects just how well understood the molecular chain of events is. One nucleotide, one amino acid, one sticky patch on a protein, and everything follows from there.